Plus Therapeutics (Nasdaq: PSTV) is a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for adults and children with rare and difficult-to-treat cancers. Our lead drug candidate REYOBIQ™ is being evaluated in the multi-center ReSPECT clinical trials for patients with recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer.
Company Details
- Employees
- 24
- Founded
- -
- Address
- 2710 Reed Rd, Suite 160,united States
- Phone
- 737.255.7194
- in****@****ics.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- plustherapeutics.com
- Keywords
- nanotechnology, oncology, cancer, liposome, drug delivery, lung cancer, breast cancer, ovarian cancer, nanomedicine, healthcare, innovation, growth, Nasdaq, brain cancer, glioblastoma, rare disease, liver cancer, radioembolization, radiopharmaceutical, PSTV.
- HQ
- Houston, Texas
Plus Therapeutics, Inc. Questions
Plus Therapeutics, Inc.'s helpline number is 737.255.7194
Plus Therapeutics, Inc.'s website is plustherapeutics.com
Plus Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/plustherapeutics
Plus Therapeutics, Inc. has
24 employees.
View email and phone details for 24
employees at Plus Therapeutics, Inc..
Plus Therapeutics, Inc.'s industry is
Pharmaceutical Manufacturing
Plus Therapeutics, Inc.'s top competitors are
Sofinnova Partners,
Perspective Therapeutics,
Latigo Biotherapeutics, Inc.,
Chimerix, A Jazz Pharmaceuticals Company,
Convergent Therapeutics, Inc.,
Gubra,
Callio Therapeutics,
Cellectar Biosciences, Inc.,
Ratio Therapeutics,
Telix Pharmaceuticals Limited.
Plus Therapeutics, Inc.'s support email address is info@plustherapeutics.com
Plus Therapeutics, Inc.'s categories are Pharmaceutical Manufacturing
Plus Therapeutics, Inc.'s founding year is 2019
